EXTON, PA, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Spherix Global Insights has released the first wave of Launch Dynamix™: Gazyva in Lupus Nephritis, providing the earliest independent read on the commercial introduction of Gazyva® (obinutuzumab, Genentech/Roche). The monthly service benchmarks uptake, perceptions, and key performance metrics during the first 18 months of launch, supplemented by quarterly deep-dive analyses across both U.S. rheumatologists and nephrologists.
In the first month of availability, both nephrologists and rheumatologists (n=129) rate Gazyva’s degree of advance above the benchmark ranges historically achieved by Benlysta (belimumab, GlaxoSmithKline) and Lupkynis (voclosporin, Aurinia Pharmaceuticals) at similar post-launch intervals during their lupus nephritis (LN) launches, an early signal of perceived clinical innovation within the market. Most specialists indicate clear intent to prescribe Gazyva within the first six months, and both rheumatologists and nephrologists report a sizeable candidate pool for treatment.
Projected utilization reinforces Gazyva’s strong early trajectory. Specialists forecast that nearly one-in-ten LN patients could be treated with the newly approved anti-CD20 monoclonal antibody within six months. Longer-term expectations also remain favorable, with nephrologists expressing slightly more aggressive views on Gazyva’s future role than rheumatologists.
These early adoption metrics illustrate the depth of enthusiasm for the brand. Specialists with greater baseline familiarity with the B-cell–targeted agent assign substantially stronger degree of advance scores; those familiar with the asset rate Gazyva significantly higher than those currently less familiar (8.5 vs. 5.6 on a 10-point scale, respectively). Familiarity also meaningfully influences estimates of patient candidacy and projected six-month share: specialists already familiar with Gazyva report more than double the number of appropriate candidates and four-fold higher six-month share projections compared with those less familiar. These patterns underscore the potential implication that as specialists deepen their knowledge of Gazyva, the therapy’s overall performance and trajectory in the LN market may further strengthen.
As subsequent monthly waves of Launch Dynamix™ are fielded, Spherix will continue to monitor Gazyva’s real-world performance across awareness, share, patient initiations, promotional reach, and evolving perceptions versus the standard of care. Combined with quarterly competitive insights from RealTime Dynamix™, stakeholders will receive a continuous, data-driven view of Gazyva’s trajectory as it establishes its presence within an increasingly dynamic LN treatment landscape.
About Launch Dynamix™
Launch Dynamix™ is an independent service providing monthly benchmarking of newly launched products for the first eighteen months of commercial availability, augmented by a quarterly deep dive into promotional activity, barriers to uptake, and patient types gravitating to the launch brand.
About RealTime Dynamix™
RealTime Dynamix™ is an independent service providing strategic guidance through quarterly or semiannual reports, which include market trending and a fresh infusion of event-driven and variable content with each wave. The reports provide an unbiased view of the competitive landscape within rapidly evolving specialty markets, fueled by robust HCP primary research and our in-house team of experts.
About Spherix Global Insights
Spherix is a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry, across the brand lifecycle.
The seasoned team of Spherix experts provides an unbiased and holistic view of the landscape within rapidly evolving specialty markets, including dermatology, gastroenterology, rheumatology, nephrology, neurology, ophthalmology, and hematology. Spherix clients stay ahead of the curve with the perspective of the extensive Spherix Physician Community.
As a trusted advisor and industry thought leader, Spherix’s unparalleled market insights and advisory services empower clients to make better decisions and unlock opportunities for growth.
To learn more about Spherix Global Insights, visit spherixglobalinsights.com or connect through LinkedIn.
For more details on Spherix’s primary market research reports and interactive dashboard offerings, visit or register here: https://clientportal.spherixglobalinsights.com
NOTICE: All company, brand or product names in this press release are trademarks of their respective holders. The findings and opinions expressed within are based on Spherix Global Insight’s analysis and do not imply a relationship with or endorsement of the companies or brands mentioned in this press release.
Lynn Price, Rheumatology Franchise Head Spherix Global Insights 4848794284 lynn.price@spherixglobalinsights.com